

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 31/195</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/23067</b> <b>(43) International Publication Date:</b> 27 April 2000 (27.04.00)
<b>(21) International Application Number:</b> PCT/US99/18981 <b>(22) International Filing Date:</b> 18 August 1999 (18.08.99) <b>(30) Priority Data:</b> 60/104,535 16 October 1998 (16.10.98) US <b>(71) Applicant (for all designated States except US):</b> WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> PANDE, Atul, Chandra [US/US]; 3355 Landings Drive, Ann Arbor, MI 48103 (US). <b>(74) Agents:</b> RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.		<b>(81) Designated States:</b> AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> METHOD FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER  <b>(57) Abstract</b>  The present invention is a novel therapeutic use of pregabalin, its derivatives, and the pharmaceutical salts thereof. The compounds are useful in the treatment of mania in all its various forms whether acute or chronic, single or recurrent, and whether or not it is associated with depression. The invention further includes the preventive treatment of bipolar disorder.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## METHOD FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER

## BACKGROUND OF THE INVENTION

United States Patent Number 5,563,175 and its family relate to compounds that are analogs of glutamic acid and gamma-aminobutyric acid (GABA).

5



10 wherein R<sub>1</sub> is a straight or branched alkyl group having from 1 to 6 carbons, phenyl, or cycloalkyl having from 3 to 6 carbons, R<sub>2</sub> is hydrogen or methyl; and R<sub>3</sub> is hydrogen, methyl, or carboxyl. The compounds are useful in antiseizure therapy and for CNS disorders such as epilepsy, Huntington's Chorea, cerebral ischemia, Parkinsonism, tardive dyskinesia, and spasticity. The compounds are  
15 recited as also possibly useful as antidepressants, anxiolytics, and antipsychotics.

United States Patent Application Serial Number 09/043358 covers the compounds of Formula I above in the treatment of pain.

United States Patent Application Serial Number 60/050736 covers the compounds of Formula I above in the treatment of inflammation.

20

United States Patent Application Serial Numbers 60/056753 and 60/074794 cover the compounds of Formula I above in the prevention and treatment of gastrointestinal damage such as inflammatory bowel disorders (IBD) and inflammatory bowel disorder (IBD).


25

United States Patent Application Serial Number 60/072397 covers the compounds of Formula I above in the treatment of skeletal and muscular pain.

There is no disclosure in the above to make obvious the present invention of the uses of the compounds of Formula I in the treatment of mania and bipolar disorder.

-2-

United States Patent Numbers 4,024,175 and 4,087,544 teach cyclic amino acids of formula



wherein R<sub>1</sub> is hydrogen or lower alkyl and n is an integer of from 4 to 6 and the  
5 pharmaceutically acceptable salts thereof.

The compounds disclosed in the above United States patents are useful for the therapy of certain cerebral diseases, for example, they can be used for the treatment of certain forms of epilepsy, faintness attacks, hypokinesia, and cranial traumas. Additionally, they bring about an improvement of cerebral functions and  
10 thus are useful in treating geriatric patients. Particularly valuable is 1-(aminomethyl)-cyclohexane-acetic acid (gabapentin).

United States Patent Number 5,084,479 teaches the compounds of the above formula for therapeutic use in neurodegenerative disorders such as Alzheimer's, Huntington's, Parkinson's, and Amyotrophic Lateral Sclerosis. It  
15 also teaches the use of the compounds in the treatment of acute brain injury such as stroke, head trauma, and asphyxia.

United States Patent Number 5,025,035 teaches the use of the compounds of the above formula for depression.

United States Patent Application Serial Number 08/281285 teaches the use  
20 of the compounds of the above formula to treat anxiety and/or panic disorders.

## SUMMARY OF THE INVENTION

The present invention relates to novel therapeutic uses of a known compound, pregabalin, its derivatives, and pharmaceutically acceptable salts. Pregabalin is (S)-3-(aminomethyl)-5-methylhexanoic acid. The invention  
25 concerns a method for treating the symptoms of mania in a human in need of such treatment. This method includes, but is not limited to the treatment of mania in all its various forms whether acute or chronic, single or recurrent episode, and

-3-

associated with depression or not. The invention further includes the preventive treatment of bipolar disorder in persons predisposed to this disorder.

Episodes of acute mania are characterized by elevated or irritable mood, disturbed sleep, grandiosity, increased motor activity, pressured thinking, distractibility and poor concentration, impaired judgment, and sometimes psychotic symptoms. The irritability can lead to outbursts of angry or aggressive behavior. Often the episodes are preceded by a period of disturbed sleep. The distractibility makes the patient move endlessly from one activity to another often to the detriment of their physical, occupational, and social well-being. The impact of these behaviors is further aggravated by the lapses of judgment and poor decision-making that is characteristic of this illness.

Episodes of mania occur in patients who suffer from bipolar disorder which is an illness characterized by alternating cycles of depression and mania. This disorder is distinct from the more common form of depression, called Major Depressive Disorder, in which patients only experience recurrent episodes of depression but no mania. Bipolar disorder can be diagnosed by the clinical evaluation of patients using the criteria specified in the Diagnostic and Statistical Manual (DSM-IV) of the American Psychiatric Association. In this nomenclature system, bipolar disorder is subsumed under the broader class of Mood Disorders and is clearly distinguished from the Anxiety Disorders and from Organic Mental Disorders.


In studies of healthy subjects and patients suffering from anxiety, pregabalin has been noted to induce sedative and calming effects. These effects will be beneficial in the symptomatic treatment of patients suffering from mania who exhibit irritability, distractibility, and poor judgment. This is a novel use for pregabalin which would not be obvious to a medical practitioner of ordinary skill.

Pregabalin has also been found to enhance sleep. This effect will be beneficial in acute mania and will also lead to reducing the risk for onset of a new episode of mania in a predisposed individual. Thus, the prophylactic use of pregabalin for bipolar disorder is also taught.

-4-

## DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to novel methods of treating mania and/or bipolar disorder in a mammal in need of such treatment. The treatment comprises administering in unit dosage form an effective amount of a compound of formula



wherein  $\text{R}_1$  is a straight or branched alkyl of from 1 to 6 carbons, phenyl, or cycloalkyl of from 3 to 6 carbons;  $\text{R}_2$  is hydrogen or methyl; and  $\text{R}_3$  is hydrogen, methyl, or carbonyl.

The most preferred compound is (S)-3-(aminomethyl)-5-methylhexanoic acid.

Pharmaceutical compositions of the compound of the present invention or its salts are produced by formulating the active compound in dosage unit form with a pharmaceutical carrier. Some examples of dosage unit forms are tablets, capsules, pills, powders, aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers containing either one or some larger number of dosage units and capable of being subdivided into individual doses. Some examples of suitable pharmaceutical carriers, including pharmaceutical diluents, are gelatin capsules; sugars such as lactose and sucrose; starches such as corn starch and potato starch, cellulose derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, and cellulose acetate phthalate; gelatin; talc; stearic acid; magnesium stearate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and oil of theobroma; propylene glycol, glycerin; sorbitol; polyethylene glycol; water; agar; alginic acid; isotonic saline, and phosphate buffer solutions; as well as other compatible substances normally used in pharmaceutical formulations. The compositions of the invention can also contain other components such as coloring agents, flavoring agents, and/or preservatives. These materials, if present, are

-5-

usually used in relatively small amounts. The compositions can, if desired, also contain other therapeutic agents.

5 The percentage of the active ingredients in the foregoing compositions can be varied within wide limits, but for practical purposes it is preferably present in a concentration of at least 10% in a solid composition and at least 2% in a primary liquid composition. The most satisfactory compositions are those in which a much higher proportion of the active ingredient is present.

10 Routes of administration of the subject compound or its salts are oral or parenteral. For example, a useful intravenous dose is between 5 and 50 mg and a useful oral dosage is between 20 and 200 mg. The dosage is within the dosing range used in epilepsy treatment or as would be with the needs of the patient as described by the physician.

A unit dosage form of the instant invention may also comprise other compounds useful in the therapy of neurodegenerative diseases.

15 The advantages of using the compounds of Formula I, especially pregabalin, in the instant invention include the relatively nontoxic nature of the compound, the ease of preparation, the fact that the compound is well-tolerated, and the ease of IV administration of the drug. Further, the drug is not metabolized in the body.

20 The subjects as used herein are mammals, including humans.

The usefulness of compounds of Formula I above and the salts thereof as agents for mania in all its various forms and in the preventative treatment of bipolar disorder is demonstrated in its effects on the mental functions of patients. These effects were observed during epilepsy clinical trial. See Table 1 below  
25 wherein the effects beneficial to healthy volunteers and anxious patients with bipolar disorder are presented.

TABLE 1

Subject No.	Symptom(s)	Effect of Pregabalin
1	Anxiety, restlessness	Calming effect, sleepiness
2	Insomnia, fearfulness	Improved sleep
3	None	Relaxation, sense of well-being
4	None	Exhilaration, relaxed feeling
5	None	Drowsiness




-7-

## CLAIMS

What is claimed is:

1. A method for treating the symptoms of mania in a mammal in need of said treatment which comprises administering a therapeutically effective amount of a compound of formula




or a pharmaceutically acceptable salt thereof wherein R<sub>1</sub> is a straight or branched alkyl of from 1 to 6 carbons, phenyl, or cycloalkyl of from 3 to 6 carbons; R<sub>2</sub> is hydrogen or methyl; and R<sub>3</sub> is hydrogen, methyl, or carbonyl.

2. A method according to Claim 1 wherein the compound administered is a compound of Formula I wherein R<sub>3</sub> and R<sub>2</sub> are hydrogen, and R<sub>1</sub> is -(CH<sub>2</sub>)<sub>0-2</sub> -i C<sub>4</sub>H<sub>9</sub> as an (R), (S), or (R, S) isomer.
3. A method according to Claim 1 wherein the compound administered is named (S)-3-(aminomethyl)-5-methylhexanoic acid or 3-aminomethyl-5-methylhexanoic acid.
4. A method according to Claim 1 wherein the mania is acute.
5. A method according to Claim 1 wherein the mania is chronic.
6. A method according to Claim 1 wherein the mania is a single episode.
7. A method according to Claim 1 wherein the mania is recurring.
8. A method according to Claim 1 wherein pregabalin is administered.

-8-

9. A method for treating and/or preventing bipolar disorder in a mammal in need of said treatment which comprises administering a therapeutically effective amount of a compound of formula



- 10 or a pharmaceutically acceptable salt thereof wherein  $\text{R}_1$  is a straight or branched alkyl of from 1 to 6 carbons, phenyl, or cycloalkyl of from 3 to 6 carbons;  $\text{R}_2$  is hydrogen or methyl; and  $\text{R}_3$  is hydrogen, methyl, or carbonyl.

10. A method according to Claim 9 wherein the compound administered is pregabalin.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/18981

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/195

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 23383 A (UNIV NORTHWESTERN) 25 November 1993 (1993-11-25) page 1, line 7-15 page 6, line 18-27 page 14, line 1-21; examples 1-3	1-10
X	WO 98 17627 A (BRYANS JUSTIN STEPHEN ;HORWELL DAVID CHRISTOPHER (GB); KNEEN CLARE) 30 April 1998 (1998-04-30) page 25, line 7 -page 26, line 1; examples 1,2 page 29, line 1 -page 30, line 3; claims 1-7,12-14	1,4-7,9
P,X	WO 99 08667 A (AKUNNE HYACINTH CHI ;HEFFNER THOMAS GARY (US); WARNER LAMBERT CO () 25 February 1999 (1999-02-25) page 1, line 17-22; claims 7-12,19-24	1-10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

1 February 2000

Date of mailing of the international search report

08/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

A. Jakobs

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/18981

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9323383 A	25-11-1993	AU 677008 B	10-04-1997
		AU 4379493 A	13-12-1993
		CA 2134674 A	25-11-1993
		CZ 9402849 A	15-03-1995
		EP 0641330 A	08-03-1995
		FI 945426 A	18-11-1994
		HU 71522 A	28-12-1995
		JP 7508288 T	14-09-1995
		MX 9302970 A	31-05-1994
		NO 944370 A	21-11-1994
		NZ 253459 A	24-03-1997
		SG 48288 A	17-04-1998
		SK 139594 A	10-05-1995
		US 5563175 A	08-10-1996
		US 5684189 A	04-11-1997
		US 5608090 A	04-03-1997
		US 5599973 A	04-02-1997
		US 5710304 A	20-01-1998
		US 5847151 A	08-12-1998
WO 9817627 A	30-04-1998	AU 4669797 A	15-05-1998
		BR 9712651 A	26-10-1999
		EP 0937032 A	25-08-1999
		HR 970560 A	31-08-1998
WO 9908667 A	25-02-1999	AU 9019198 A	08-03-1999